Serhat KARADAVUT, İsmail ALTINTOP

Distribution of arrhythmic events in COVID-19 patients receiving favipiravir and hydroxychloroquine

Aim: Favipiravir, first used for novel influenza strains, is used today in coronavirus disease 2019 (COVID-19). While many studies have been reported in the literature on hydroxychloroquine’s (HQ) arrhythmogenic adverse effects, data on favipiravir are limited. The authors purposed to demonstrate that the arrhythmic effects of favipiravir are not negligible. Materials and Methods: The researchers conducted a retrospective observational study on 194 COVID-19 patients. The study population was classified into two groups based on the treatment regimen: favipiravir (n=101) and HQ (n=93). Pre/post-medication electrocardiograms were evaluated for arrhythmic events. Results: Twenty of 101 (19.8%) subjects in the favipiravir group and 13 of 93 (13.9%) subjects in the HQ group had arrhythmogenic events (p=0.42). The most frequent arrhythmic events in the favipiravir group were sinus bradycardia (13 of 20, 65%) and third-degree atrioventricular block (4 of 20, 20%). Corrected QT (QTc) prolongation was the most seen arrhythmogenic adverse effect (9 of 13, 69%) in the HQ group. The proportion of patients with prolonged QTc were higher in the HQ group than the favipiravir group (9 vs. 3, p=0.04). However, the difference between final and baseline QTc did not differ between the HQ and the favipiravir group (11 [IQR:-9—57] vs. 12 [IQR:-7—103], p=0.59, respectively). The change between pre and post-treatment heart rate was more remarkable in the favipiravir group than the HQ group (12 [IQR:-6—70] vs. 5 [IQR:-8—41], p < 0.001, respectively). Conclusions: Favipiravir was significantly associated with sinus bradycardia requiring drug withdrawal. Clinicians should more routinely implement arrhythmia monitoring for patients receiving favipiravir.

PDF

___

1. Search of: COVID-19 - List Results - ClinicalTrials.gov [Internet]. [cited 2021 Feb 15]. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19
2. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036–41.
3. Jankelson L, Karam G, Becker ML, et al. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm. 2020 Sep;17(9):1472–9.
4. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis [Internet]. 2019;32(2).
5. Vanderlinden E, Vrancken B, Van Houdt J, et al. Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother. 2016;60(11):6679–91.
6. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192–8.
7. Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020;
8. Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I, et al. Major neurologic adverse drug reactions, potential drug-drug interactions and pharmacokinetic aspects of drugs used in covid-19 patients with stroke: A narrative review. Ther Clin Risk Manag. 2020;16:595.
9. Borobia AM, Mora-Rillo M, Olivencia GR, et al. High dose favipiravir: first experience in a patient with Ebola. Clin Ther. 2015;37(8):e15–6.
10. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir–a potential treatment in the COVID-19 pandemic? J virus Erad. 2020;6(2):45–51.
11. Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020 Sep;17(9):1425–33.
12. Saleh M, Gabriels J, Chang D, et al. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662.
13. BURRELL ZLJ, MARTINEZ AC. Chloroquine and hydroxychloroquine in the treatment of cardiac arrhythmias. N Engl J Med. 1958 Apr;258(16):798–800.
14. Wilders R, Verkerk AO. Long QT Syndrome and Sinus Bradycardia-A Mini-Review. Front Cardiovasc Med. 2018;5:106.
15. Khan Q, Ismail M, Haider I. High prevalence of the risk factors for QT interval prolongation and associated drugdrug interactions in coronary care units. Postgrad Med. 2018 Nov;130(8):660–5.
16. Chen C-Y, Wang F-L, Lin C-C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173–5.
17. Naksuk N, Lazar S, Peeraphatdit T. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Hear J Acute Cardiovasc Care. 2020;9(3):215–21.
18. Kaur RJ, Charan J, Dutta S, et al. Favipiravir Use in COVID19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. Infect Drug Resist. 2020;13:4427–38.
19. Michaud V, Dow P, Al Rihani SB, et al. Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs. Clin Transl Sci. 2021 Jan;14(1):20–8.
20. Chinello P, Petrosillo N, Pittalis S, et al. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis. 2017 Dec;11(12):e0006034.
21. Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann noninvasive Electrocardiol Off J Int Soc Holter Noninvasive Electrocardiology, Inc. 2006 Jan;11(1):52–6.
22. Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003 Apr;73(4):292–303.
23. Strle F, Maraspin V. Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr. 2002 Jun;114(10–11):396–9.
24. Kezerashvili A, Khattak H, Barsky A, et al. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol an Int J Arrhythm pacing. 2007 Apr;18(3):243–6.
25. Avedissian SN, Rhodes NJ, Ng TMH, et al. The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients. Pharmacotherapy. 2019 Jun;39(6):718–23.